Biosortia-at scale mining of nature’s metabolite bounty

Biosortia is building the world’s largest library of microbiome-derived compounds for therapeutic and other applications, by leveraging the company’s microbial harvesting platform to sample and mine aquatic microbiomes at unprecedented scales with sustainable and environmentally friendly approaches. Biosortia is seeking partners interested in accessing compounds and chemistries to develop biologically relevant small molecule leads.

Biosortia Pharmaceuticals, a microbiome company founded in 2012, has developed a unique platform for accessing the hidden chemistry of aquatic microorganisms to generate new opportunities for drug discovery. With more than 25% of all marketed drugs over the past 50–60 years having been inspired by or developed from natural products obtained from cultured microorganisms, further exploitation of this approach seems an obvious path. However, the pipeline of compounds is rapidly running dry—only about one percent of microorganisms in all environments have been cultured. Unlocking the chemistry of the remaining 99% of microorganisms, the ‘unculturable’ fraction, to obtain drug-like natural compounds could have a substantial impact on multibillion-dollar industries, including biopharma, agriculture, and consumer/cosmetic applications.